Format

Send to

Choose Destination
Expert Opin Pharmacother. 2017 Jul;18(10):957-964. doi: 10.1080/14656566.2017.1340940. Epub 2017 Jun 16.

Pharmacotherapy for community-acquired pneumonia in the elderly.

Author information

1
a Health Sciences Division, Faculty of Medicine , Hospital Universidad del Norte and Universidad del Norte , Barranquilla , Colombia.
2
b Infectious Disease Department, Hospital Universitari de Bellvitge - IDIBELL, Spanish Network for Research in Infectious Diseases (REIPI), and Clinical Sciences Department, Faculty of Medicine , University of Barcelona , Barcelona , Spain.

Abstract

Community-acquired pneumonia (CAP) is an increasing problem in the elderly that is associated with elevated morbidity and mortality. Given the expected increased life expectancy, this problem is only likely to worsen, so it has been considered that treatment effects must be examined separately in elderly adults with CAP. Areas covered: In this narrative review, we give an update of the available data of antibiotics for elderly patients with CAP. Clinical features, drug pharmacokinetics and pharmacodynamics, adverse effects, and outcomes differ in CAP depending on patient age. Older age, for example, can affect the effect of specific antibiotic regimens on important CAP clinical outcomes. Current guidelines do not offer specific recommendations for the management of CAP in elderly patients. Expert opinion: Most of our knowledge about the treatment of CAP in elderly patients has been gained from studies in young populations. However, elderly patients with CAP deserve special attention because there are several factors in this population that could influence their response to antibiotic regimens in CAP.

KEYWORDS:

Antibiotic; community-acquired pneumonia; elderly; treatment

PMID:
28602108
DOI:
10.1080/14656566.2017.1340940
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center